{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:18:00Z","timestamp":1774948680415,"version":"3.50.1"},"posted":{"date-parts":[[2026,3,27]]},"group-title":"Infectious Diseases (except HIV\/AIDS)","reference-count":64,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,3,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Dengue is the canonical viral disease for which immune history predicts protective versus pathogenic responses and immunogenicity. Yet, due to limitations in animal models and clinical presentation after peak viremia, how pre-infection and early immune responses affect dengue outcomes is not confirmed. We conducted a phase 1 clinical trial with 45 healthy adults to test if secondary infection challenge with a heterotypic, full-length, attenuated virus increases viremia and immunogenicity compared to primary and tertiary infection. Viremia was associated with more, but still mild, clinical signs and symptoms, and secondary infection predicted greater viremia and neutralizing antibodies. However, those with the highest baseline enhancing antibodies experienced delayed inflammatory and adaptive activation, the highest viremia, strong acute immune responses, but waning of potent CD8\n                  <jats:sup>+<\/jats:sup>\n                  T cells and antibodies. Baseline antibodies to non-structural protein 1 of multiple serotypes predicted early interferon and balanced immune activation, viremia control, and development of enduring, potent B and T cells, revealing how vaccines can induce broad long-lasting protection. Finally, these antibody and T cell profiles at baseline predicted sterilization of infection. We demonstrate that controlled human challenge can delineate coordinated versus dysregulated acute responses and effects on immunogenicity, informing therapeutic and vaccine strategies for dengue and other viral diseases.\n                <\/jats:p>","DOI":"10.64898\/2026.03.26.26349424","type":"posted-content","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:20:23Z","timestamp":1774657223000},"source":"Crossref","is-referenced-by-count":0,"title":["Enhancing, controlling, and sterilizing dengue immunity and the development of broadly protective responses"],"prefix":"10.64898","author":[{"given":"Camila D.","family":"Odio","sequence":"first","affiliation":[{"name":"Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemary A.","family":"Aogo","sequence":"additional","affiliation":[{"name":"Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saba","family":"Firdous","sequence":"additional","affiliation":[{"name":"Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlie","family":"Voirin","sequence":"additional","affiliation":[{"name":"Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Blanco-Rivera","sequence":"additional","affiliation":[{"name":"Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelsey E.","family":"Lowman","sequence":"additional","affiliation":[{"name":"Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA"},{"name":"Laboratory of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nhyira","family":"Asante","sequence":"additional","affiliation":[{"name":"Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ysabelle","family":"Broderson","sequence":"additional","affiliation":[{"name":"Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keerthi","family":"Konda","sequence":"additional","affiliation":[{"name":"Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe M.","family":"Hasund","sequence":"additional","affiliation":[{"name":"Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amparo","family":"Martinez-Perez","sequence":"additional","affiliation":[{"name":"Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick I.","family":"Mpingabo","sequence":"additional","affiliation":[{"name":"Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Law","sequence":"additional","affiliation":[{"name":"Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlin","family":"Jarvis","sequence":"additional","affiliation":[{"name":"Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviane","family":"Callier","sequence":"additional","affiliation":[{"name":"Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Hunsberger","sequence":"additional","affiliation":[{"name":"Division of Clinical Research, Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Abad","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aravinda","family":"de Silva","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robbie","family":"Kattappuram","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, NIH Clinical Center, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gitanjali","family":"Bhushan","sequence":"additional","affiliation":[{"name":"Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3470-9598","authenticated-orcid":false,"given":"Christina","family":"Yek","sequence":"additional","affiliation":[{"name":"International Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Phnom Penh, Cambodia"},{"name":"Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Manning","sequence":"additional","affiliation":[{"name":"International Center of Excellence in Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Phnom Penh, Cambodia"},{"name":"Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna P.","family":"Durbin","sequence":"additional","affiliation":[{"name":"Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey I.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Medical Virology Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Weiskopf","sequence":"additional","affiliation":[{"name":"Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA"},{"name":"Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego (UCSD), La Jolla, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen S.","family":"Whitehead","sequence":"additional","affiliation":[{"name":"Arbovirus Vaccine Research Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1033-6758","authenticated-orcid":false,"given":"Leah C.","family":"Katzelnick","sequence":"additional","affiliation":[{"name":"Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2026033101200568000_2026.03.26.26349424v1.1","doi-asserted-by":"crossref","unstructured":"Cattarino, L. , Rodriguez-Barraquer, I. , Imai, N. , Cummings, D.A.T. & Ferguson, N.M . Mapping global variation in dengue transmission intensity. Sci Transl Med 12 (2020).","DOI":"10.1126\/scitranslmed.aax4144"},{"key":"2026033101200568000_2026.03.26.26349424v1.2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit273"},{"key":"2026033101200568000_2026.03.26.26349424v1.3","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2007.77.910"},{"key":"2026033101200568000_2026.03.26.26349424v1.4","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/140.4.527"},{"key":"2026033101200568000_2026.03.26.26349424v1.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0157-4"},{"key":"2026033101200568000_2026.03.26.26349424v1.6","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6836"},{"key":"2026033101200568000_2026.03.26.26349424v1.7","doi-asserted-by":"crossref","unstructured":"Vuong, N.L. et al. Dengue viremia kinetics and effects on platelet count and clinical outcomes: An analysis of 2340 patients from Vietnam. Elife 13, RP92606 (2024).","DOI":"10.7554\/eLife.92606.3"},{"key":"2026033101200568000_2026.03.26.26349424v1.8","doi-asserted-by":"crossref","unstructured":"Mpingabo, P.I. et al. Protective envelope dimer epitope-like antibodies are elicited against dengue virus in children after infection and vaccination. Sci Transl Med 17, eadq0571 (2025).","DOI":"10.1126\/scitranslmed.adq0571"},{"key":"2026033101200568000_2026.03.26.26349424v1.9","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir012"},{"key":"2026033101200568000_2026.03.26.26349424v1.10","doi-asserted-by":"crossref","first-page":"e179771","DOI":"10.1172\/jci.insight.179771","article-title":"Frequency of dengue virus-specific T cells is related to infection outcome in endemic settings.","volume":"10","year":"2025","journal-title":"JCI Insight"},{"key":"2026033101200568000_2026.03.26.26349424v1.11","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3058"},{"key":"2026033101200568000_2026.03.26.26349424v1.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07539-1"},{"key":"2026033101200568000_2026.03.26.26349424v1.13","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12900"},{"key":"2026033101200568000_2026.03.26.26349424v1.14","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/j.immuni.2025.05.020","article-title":"A conserved immune dysregulation signature is associated with infection severity, risk factors prior to infection, and treatment response","volume":"58","year":"2025","journal-title":"Immunity"},{"key":"2026033101200568000_2026.03.26.26349424v1.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800820"},{"key":"2026033101200568000_2026.03.26.26349424v1.16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab864"},{"key":"2026033101200568000_2026.03.26.26349424v1.17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2301790"},{"key":"2026033101200568000_2026.03.26.26349424v1.18","doi-asserted-by":"crossref","unstructured":"Nivarthi, U.K. et al. A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans. Nat Commun 12, 1102 (2021).","DOI":"10.1038\/s41467-021-21384-0"},{"key":"2026033101200568000_2026.03.26.26349424v1.19","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02129-14"},{"key":"2026033101200568000_2026.03.26.26349424v1.20","doi-asserted-by":"crossref","first-page":"e157811","DOI":"10.1172\/jci.insight.157811","article-title":"The innate immune response following multivalent dengue vaccination and implications for protection against dengue challenge.","volume":"7","year":"2022","journal-title":"JCI Insight"},{"key":"2026033101200568000_2026.03.26.26349424v1.21","doi-asserted-by":"crossref","unstructured":"Tu, H.A. et al. Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003. Cell Rep Med 1, 100155 (2020).","DOI":"10.1016\/j.xcrm.2020.100155"},{"key":"2026033101200568000_2026.03.26.26349424v1.22","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix609"},{"key":"2026033101200568000_2026.03.26.26349424v1.23","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc0476"},{"key":"2026033101200568000_2026.03.26.26349424v1.24","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S1473-3099(24)00100-2","article-title":"Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial","volume":"24","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026033101200568000_2026.03.26.26349424v1.25","doi-asserted-by":"crossref","unstructured":"Odio, C.D. et al. Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine. BMC Infect Dis 23, 345 (2023).","DOI":"10.1186\/s12879-023-08299-5"},{"key":"2026033101200568000_2026.03.26.26349424v1.26","doi-asserted-by":"crossref","unstructured":"Maciejewski, S. et al. Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. Sci Transl Med 12 (2020).","DOI":"10.1126\/scitranslmed.aaw9066"},{"key":"2026033101200568000_2026.03.26.26349424v1.27","doi-asserted-by":"crossref","unstructured":"Odio, C.D. et al. Dengue virus IgG and neutralizing antibody titers measured with standard and mature viruses are protective. Nat Commun 16, 191 (2025).","DOI":"10.1038\/s41467-024-53916-9"},{"key":"2026033101200568000_2026.03.26.26349424v1.28","doi-asserted-by":"crossref","unstructured":"Bos, S. et al. Protection against symptomatic dengue infection by neutralizing antibodies varies by infection history and infecting serotype. Nat Commun 15, 382 (2024).","DOI":"10.1038\/s41467-023-44330-8"},{"key":"2026033101200568000_2026.03.26.26349424v1.29","doi-asserted-by":"publisher","DOI":"10.1038\/265739a0"},{"key":"2026033101200568000_2026.03.26.26349424v1.30","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70166-3"},{"key":"2026033101200568000_2026.03.26.26349424v1.31","doi-asserted-by":"crossref","unstructured":"Chan, C.Y.Y. , et al. Antibody-Dependent Dengue Virus Entry Modulates Cell Intrinsic Responses for Enhanced Infection. mSphere 4 (2019).","DOI":"10.1128\/mSphere.00528-19"},{"key":"2026033101200568000_2026.03.26.26349424v1.32","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.chom.2025.06.006","article-title":"Immune profiling in subclinical secondary dengue-infected cases reveals adaptive immune signatures correlated to protection from severe dengue","volume":"33","year":"2025","journal-title":"Cell Host Microbe"},{"key":"2026033101200568000_2026.03.26.26349424v1.33","doi-asserted-by":"publisher","DOI":"10.1126\/science.aai8128"},{"key":"2026033101200568000_2026.03.26.26349424v1.34","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1989.40.444"},{"key":"2026033101200568000_2026.03.26.26349424v1.35","doi-asserted-by":"crossref","unstructured":"Thulin, N.K. et al. Maternal Anti-Dengue IgG Fucosylation Predicts Susceptibility to Dengue Disease in Infants. Cell Rep 31, 107642 (2020).","DOI":"10.1016\/j.celrep.2020.107642"},{"key":"2026033101200568000_2026.03.26.26349424v1.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2014.06.001"},{"key":"2026033101200568000_2026.03.26.26349424v1.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01654-3"},{"key":"2026033101200568000_2026.03.26.26349424v1.38","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-017-0625-1"},{"key":"2026033101200568000_2026.03.26.26349424v1.39","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01424-16"},{"key":"2026033101200568000_2026.03.26.26349424v1.40","doi-asserted-by":"crossref","unstructured":"Ichise, H. et al. Rebalancing viral and immune damage versus repair prevents death from lethal influenza infection. Science 390, eadr4635 (2025).","DOI":"10.1126\/science.adr4635"},{"key":"2026033101200568000_2026.03.26.26349424v1.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2022.12.008"},{"key":"2026033101200568000_2026.03.26.26349424v1.42","doi-asserted-by":"crossref","unstructured":"Huyen, T.B. et al. Anakinra for dengue patients with hyperinflammation: protocol for a randomized double-blind placebo-controlled trial. Wellcome Open Res 9, 689 (2024).","DOI":"10.12688\/wellcomeopenres.21017.1"},{"key":"2026033101200568000_2026.03.26.26349424v1.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01109-6"},{"key":"2026033101200568000_2026.03.26.26349424v1.44","doi-asserted-by":"crossref","first-page":"e147066","DOI":"10.1172\/JCI147066","article-title":"Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection","volume":"131","year":"2021","journal-title":"J Clin Invest"},{"key":"2026033101200568000_2026.03.26.26349424v1.45","doi-asserted-by":"crossref","unstructured":"Muller, D.A. et al. Kinetics of NS1 and anti-NS1 IgG following dengue infection reveals likely early formation of immune complexes in secondary infected patients. Sci Rep 15, 6684 (2025).","DOI":"10.1038\/s41598-025-91099-5"},{"key":"2026033101200568000_2026.03.26.26349424v1.46","first-page":"e02147","article-title":"Human CD4(+) T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity","volume":"91","year":"2017","journal-title":"J Virol"},{"key":"2026033101200568000_2026.03.26.26349424v1.47","unstructured":"Cirelli, K.M. et al. Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance. Cell 180, 206 (2020)."},{"key":"2026033101200568000_2026.03.26.26349424v1.48","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad5651"},{"key":"2026033101200568000_2026.03.26.26349424v1.49","doi-asserted-by":"publisher","DOI":"10.1172\/JCI128426"},{"key":"2026033101200568000_2026.03.26.26349424v1.50","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.10358"},{"key":"2026033101200568000_2026.03.26.26349424v1.51","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1007\/s00705-015-2519-7","article-title":"Higher levels of dengue-virus-specific IgG and IgA during pre-defervescence associated with primary dengue hemorrhagic fever","volume":"160","year":"2015","journal-title":"Arch Virol"},{"key":"2026033101200568000_2026.03.26.26349424v1.52","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.20-1111"},{"key":"2026033101200568000_2026.03.26.26349424v1.53","doi-asserted-by":"crossref","unstructured":"Vuong, N.L. et al. C-reactive protein as a potential biomarker for disease progression in dengue: a multi-country observational study. BMC Med 18, 35 (2020).","DOI":"10.1186\/s12916-020-1496-1"},{"key":"2026033101200568000_2026.03.26.26349424v1.54","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00386-22"},{"key":"2026033101200568000_2026.03.26.26349424v1.55","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.virol.2016.06.022","article-title":"Enhancing dengue virus maturation using a stable furin over-expressing cell line","volume":"497","year":"2016","journal-title":"Virology"},{"key":"2026033101200568000_2026.03.26.26349424v1.56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006862"},{"key":"2026033101200568000_2026.03.26.26349424v1.57","doi-asserted-by":"crossref","unstructured":"Sidney, J. , Peters, B. & Sette, A . Epitope prediction and identification- adaptive T cell responses in humans. Semin Immunol 50, 101418 (2020).","DOI":"10.1016\/j.smim.2020.101418"},{"key":"2026033101200568000_2026.03.26.26349424v1.58","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.934"},{"key":"2026033101200568000_2026.03.26.26349424v1.59","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv289"},{"key":"2026033101200568000_2026.03.26.26349424v1.60","doi-asserted-by":"crossref","unstructured":"Grifoni, A. et al. Global Assessment of Dengue Virus-Specific CD4(+) T Cell Responses in Dengue-Endemic Areas. Front Immunol 8, 1309 (2017).","DOI":"10.3389\/fimmu.2017.01309"},{"key":"2026033101200568000_2026.03.26.26349424v1.61","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41564-023-01421-y","article-title":"Human FcgammaRIIIa activation on splenic macrophages drives dengue pathogenesis in mice","volume":"8","year":"2023","journal-title":"Nat Microbiol"},{"key":"2026033101200568000_2026.03.26.26349424v1.62","doi-asserted-by":"crossref","unstructured":"Phan, T.T.N. et al. A conserved set of mutations for stabilizing soluble envelope protein dimers from dengue and Zika viruses to advance the development of subunit vaccines. J Biol Chem 298, 102079 (2022).","DOI":"10.1016\/j.jbc.2022.102079"},{"key":"2026033101200568000_2026.03.26.26349424v1.63","doi-asserted-by":"crossref","unstructured":"Kudlacek, S.T. et al. Designed, highly expressing, thermostable dengue virus 2 envelope protein dimers elicit quaternary epitope antibodies. Sci Adv 7, eabg4084 (2021).","DOI":"10.1126\/sciadv.abg4084"},{"key":"2026033101200568000_2026.03.26.26349424v1.64","doi-asserted-by":"crossref","unstructured":"Hein, L.D. et al. Multiplex sample-sparing assay for detecting type-specific antibodies to Zika and dengue viruses: an assay development and validation study. Lancet Microbe 6, 100951 (2025).","DOI":"10.1016\/j.lanmic.2024.07.014"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.03.26.26349424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:20:24Z","timestamp":1774945224000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.03.26.26349424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":64,"URL":"https:\/\/doi.org\/10.64898\/2026.03.26.26349424","relation":{},"subject":[],"published":{"date-parts":[[2026,3,27]]},"subtype":"preprint"}}